Antithrombotic therapy in 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease

Antithrombotic therapy in 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease, Published online: 03 January 2018; doi:10.1038/nrcardio.2017.212

In 2017, several high-impact studies in thrombosis were published. Refinements were made in the optimal therapy for patients with stable atherosclerosis or with atrial fibrillation undergoing percutaneous coronary intervention. Risk scores to determine duration of antiplatelet therapy were developed. The potential risk of subclinical valve leaflet thrombosis was identified.

中文翻译：

---

2017年抗血栓治疗：动脉粥样硬化，心房颤动和瓣膜疾病的进展

2017年抗血栓治疗：动脉粥样硬化，心房颤动和瓣膜疾病的进展

2017年抗血栓治疗：动脉粥样硬化，心房颤动和瓣膜疾病的进展，在线发布：2018年1月3日; doi：10.1038 / nrcardio.2017.212

2017年，发表了几篇关于血栓形成的高影响力研究。对于稳定的动脉粥样硬化或心房颤动经皮冠状动脉介入治疗的患者，在最佳治疗方案中进行了细化。确定了抗血小板治疗持续时间的风险评分。确定了亚临床瓣膜小叶血栓形成的潜在风险。